Home / Transcripts / STAAR Surgical Company (STAA) · March 3, 2026

STAAR Surgical Company (STAA) Earnings Call Transcript

March 3, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 50 min

Earnings Call Speaker Segments

Connie Johnson executive
#1

Thanks so much, operator. Good afternoon, everyone, and I appreciate you being with us. Joining us on today's call are Warren Foust, who serves as Interim Co-CEO, President and Chief Operating Officer of STAAR Surgical, along with Deborah Andrews, Interim Co-CEO and Chief Financial Officer of STAAR Surgical. We issued our results for the fourth quarter and fiscal 2025 earlier today through a press release and Form 8-K. Both our results release and shareholder letter are now available on our investor website, investors.staar.com. This call is set to run for 1 hour, and it will feature Q&A for publishing analysts. Those of you on the webcast can also email questions for today's Q&A session to ir@staar.com. Before we begin, please note that we will be making forward-looking statements during today's discussion. Such statements carry risks and uncertainties that could lead actual results to differ materially from what those forward-looking statements express or imply. I'd urge you to review the disclaimers in today's release and the shareholder letter, along with the disclosures in our SEC filings. Unless the law requires it, STAAR takes on no obligation to update these forward-looking statements to reflect future events or actual outcomes. Also, during today's discussion, we will reference certain non-GAAP financial measures, including adjusted EBITDA and constant currency sales. Definitions and reconciliations of non-GAAP metrics can be found in today's release. For the sake of brevity, all comparisons on today's call will be on a year-over-year basis against the relevant period, unless otherwise specified. One last quick note: we plan to use our website as a channel for disclosing material nonpublic information and for meeting our disclosure obligations under Regulation FD. Those disclosures will appear in the Investor Relations section of our website. As a result, investors should keep an eye on our investor website, in addition to following our press releases, SEC filings and public conference calls and webcasts. With that, I'll hand the presentation over to Warren Foust, our Interim Co-CEO. Warren?

Warren Foust executive
#2

Hello, everybody, and thank you for joining us this afternoon. Deborah and I are pleased to be here with you for this call, which marks our first discussion of quarterly results since we stepped into the Interim Co-CEO positions. Before diving into specifics, I'd like to address the way our leadership is set up. As of February 1st, Deborah and I assumed the shared Co-CEO role, and we are guiding the company jointly on an interim basis. This change provides continuity. Throughout the past year, Deborah and I collaborated very closely in our roles as Chief Financial Officer and as President and Chief Operating Officer, and that working relationship has positioned us well for what lies ahead. The things we're good at and the fields we know best fit together well, and when it comes to both what we prioritize and how we carry it out, we see eye to eye. To find STAAR's incoming Chief Executive Officer, the company's Board of Directors has engaged Egon Zehnder, a top worldwide firm specializing in executive recruitment and leadership guidance. People from inside the company as well as those from outside will be evaluated for that role. Looking at STAAR, 2025 proved to be a tough twelve months full of change. As we see it, 2026 should shape up to be far stronger — a period marked by expansion, better earnings, and real strides throughout our pipeline of innovations, and we intend to go over all of that during today's call. Per what Connie mentioned, we've put out a letter to shareholders alongside the results we released today. It offers our take on 2025 and lays out what we intend to do and how we'll go about it in 2026. Deborah and I are fortunate to know STAAR's operations intimately and to be deeply involved in them. Following a stretch of uncertainty, we're partnering with our teams to review our portfolio and road map, and we're establishing unambiguous expectations regarding how the business runs as well as its financial results, so that we can unleash what our 2026 plan for growth, profit and innovation can deliver. The way 2026 has begun gives us reason for optimism. Our team is motivated and getting things done. My schedule is packed with interactions involving customers, gatherings with distributors, all-hands company meetings, sessions to align our leadership, and worldwide commercial launch events centered on clinical education, getting our commercial side ready, improving how our sales teams perform, and keeping our messaging consistent. There's real enthusiasm among our teams, since in the majority of markets, surgery for refractive correction keeps shifting in favor of procedures using lenses rather than the laser-based vision correction that involves removing corneal tissue. Even while the wider laser vision correction sector faces difficulties, EVO ICL keeps picking up additional share. As a result, STAAR is in a strong position to speed growth back up in markets where we already operate and to open up possibilities through the new products we're introducing. Turning to China, which remains our biggest market: following a stretch of years marked by macro instability tied to COVID, softness in housing, and inconsistent consumer outlays, the environment settled down during 2025 thanks to greater policy backing and a sharp climb in the equity market. Demand for EVO ICL within the market came back at a mid-single-digit pace, and procedure volumes strengthened as the year came to a close. Even so, that rebound did not show up as China net sales growth for STAAR in 2025, since our distributors trimmed their inventory. Still, it leaves us feeling optimistic about 2026. The setup in China looks ready for an upswing, and that should help fuel STAAR's growth. Beyond China, there are also grounds for optimism regarding STAAR's upcoming growth; despite the persistent decrease in laser vision correction procedures, momentum is evident within our U.S. operations. Plus, thanks to the broader age range indication for EVO we recently announced for the United States — cleared now for treating myopia in adults from 21 through 60 — the opportunity before us has grown larger. That broader indication translates into approximately 8 million additional potential EVO candidates across the United States. Our push to widen EVO's labeling is driving growth in other regions of the world too. In Brazil, for instance, EVO was earlier cleared down to minus 6 diopters, and today it may be used to treat myopia down to minus 0.5 diopters. Steady growth continues throughout the Americas, and we anticipate further expansion in Canada come 2026; during 2025, we moved to a direct model in Canada. Though that team is small, results there are already delivering. During 2026, we aim for solid EVO growth across EMEA and in Asia Pacific markets including Japan, Korea and India. India especially, where a foundation is being laid, offers a growing opportunity since its economy is expanding rapidly and an increasing share of its people can afford refractive surgery. We feel just as positive about what's possible in the Taiwan market, and that's a place where we secured regulatory approval during 2025. Turning to profitability, we made a lot of headway there in 2025, and it's going to stay a top priority all through 2026. Over the course of 2025, we cut costs and brought down our annualized adjusted operating expense run rate, which put us past the $225 million goal for the second half that we told investors about in Q1 2025. When revenue grows, staying disciplined on costs ought to produce operating leverage. What we're aiming at is impact across the whole enterprise, not just piecemeal gains, along with fresh approaches to how we work that make decisions happen faster, so that our actions turn into results and returns more quickly. Profitability expansion stems from cutting costs across the enterprise, yet it also stems from disciplined investing; we pursue opportunities both big and small, among them manufacturing and infrastructure improvements, and we constantly seek margin improvement chances within our sales and distribution network. We further believe that optimizing ASPs can help boost profitability. Capital is allocated where impact is greatest — the right programs in the right markets, backed by the right people and infrastructure. On that note, we're in the final stages of implementing Oracle ERP, which will modernize how we operate across the enterprise. Full deployment is anticipated early in the second half of the year. Beyond ERP, we're making headway on Stella — our next-gen platform for online sizing and ordering — which reduces the difficulty of bringing EVO ICL technology on board. On top of that, we're advancing other IT efforts that reach from enhancements in manufacturing processes all the way to enabling our sales force. Our belief is that these investments will deliver returns for the surgeons we serve and their patients, while also driving efficiency and profitability across the entire company. You can see a fresh commitment to innovation in our 2026 plan, which targets growth, profit and innovation alike. I'm pleased to report that EVO+ is now available in China, and our rollout continues to advance as we expand Swiss manufacturing capacity to meet demand. In China, EVO+ is the first new lens we've introduced in over 10 years. The early demand has been encouraging, and as production scales we're working to boost supply. Eventually, we anticipate that EVO+ in China will bring higher ASPs and margin expansion. Also in 2026, we're broadening where the Lioli injector can be purchased commercially for EVO ICL procedures. The Lioli injector is already well established in the United States, and we're glad to offer this new injector choice to surgeons in EMEA. These near-term launches have us excited, though we're equally focused on our longer-term pipeline. New capabilities are being built, and our teams are setting clear milestones and time lines for future advancements, along with the operational discipline and accountability needed to remain on track in a market that's rapidly evolving. Before turning things to Deborah, I believe it's worth acknowledging that 2025 is behind us now and the disruption from our proposed merger with Alcon is no longer in front of us. Our shareholders have made their voices heard in support of a long-term approach, and we hear them, embracing what's possible for STAAR as a stand-alone company. We strongly believe STAAR possesses all that's needed to achieve our growth, profitability and innovation goals; our technology is superior. Our differentiated Collamer material serves as the basis for our EVO technology and has no equal in the market. STAAR alone has more than 40 years of history treating myopia through our innovative lens-based procedure; and the epidemics of myopia and dry eye disease are only worsening. We hold trusted relationships with our partners. The STAAR surgeon community feels passionately about EVO ICLs and about delivering the benefits of lens-based vision correction without corneal tissue removal to their patients. This devoted customer base carries real, tangible power. Our team is talented. Our dedicated employees and the STAAR leadership team are aligned and focused, and they have what it takes to execute our goals and objectives and drive stockholder value creation. At this point, I'll hand the floor over to Deborah, who serves alongside me as Co-CEO, so she can add a few thoughts and walk everyone through the numbers. Deborah, over to you.

Deborah Andrews executive
#3

Thank you, Warren. It's a pleasure to be on the call with all of you today, and I'm honored to serve alongside you as Co-CEO leading the STAAR organization. As Warren mentioned, during 2025 we implemented several measures aimed at cutting costs and boosting profitability. One of the key initiatives in 2025 involved tackling our China inventory situation to set STAAR up for growth ahead. The biggest operational hurdle we faced in 2025 was navigating the rebalancing of product inventory in China after demand softened in 2024; that year brought a double-digit drop in in-market EVO ICL sales along with elevated inventory levels; our response was to intentionally halt shipments, bring channel inventory back to normal and tighten distributor discipline. Those steps hurt, but they were needed. By late 2025, inventory sitting with our distributor customers in China had fallen to contractual levels. In-market sales and procedures picked up and business momentum started coming back. As we've discussed before, our December 2024 China shipment added to elevated inventory levels. That $27.5 million shipment was consumed during fiscal 2025. And by the close of Q3, we had fully recognized the revenue tied to the December 2024 China shipment. For much of this stretch, STAAR lacked full visibility into downstream inventory levels or actual EVO ICL procedure volumes. Over the past year, we've put time and effort into more comprehensive data processes and analyses that now deliver improved and still developing insight into inventories across the channel. While that work continues, our visibility has gotten materially better and will keep strengthening. Let me briefly touch on tariffs and Swiss manufacturing. We're happy to report that we responded quickly in 2025 when rising China-U.S. tariffs created additional headwinds for our business. We managed to mitigate near-term exposure by deploying temporary consignment inventory and leveraging existing China held inventory, while speeding up manufacturing expansion in Nidau, Switzerland. Our Swiss facility is now producing commercial product and is focused on EVO+ for China. Products made in Switzerland aren't subject to U.S.-China tariffs, which will help in the near-term as we roll out EVO+ in China. We believe Swiss manufacturing can deliver long-term benefits as we look to manufacture EVO and EVO+ for China down the road. Swiss manufacturing not only helps reduce tariff exposure, but it gives us flexibility and scale to support sustained growth and significantly boosts our long-term supply chain resilience. Now I'd like to move to fourth quarter results. I'll begin with fourth quarter sales performance, then margins, profitability and cash. Total net sales for the quarter came in at $57.8 million compared to $49 million in the year-ago quarter, driven by a lower-than-expected rebound in sales in China, partially offset by growth in Americas and non-China APAC regions. China net sales were $17.5 million in the fourth quarter of 2025 compared to $7.8 million in the year-ago quarter. During the quarter, certain China subdistributors and customers sent some inventory back to our distributors, which resulted in lower-than-anticipated fourth quarter net sales for STAAR. Our view is that this stemmed mostly from concerns regarding what lies ahead for them should Alcon succeed in acquiring the company; that same uncertainty had an effect on sales made to distributors in other regions of the world as well. Although these disturbances weighed down our results for the fourth quarter, we expect that lower levels of distributor inventory will translate into better net sales for STAAR during 2026 and afterward. If we set China aside, net sales were down 2% versus the same period a year earlier, as the Americas rose 18% in Q4, EMEA fell 20% in Q4 — a decline driven by a distributor transition in the Middle East along with distributor dynamics throughout the region stemming from the proposed Alcon merger — and APAC excluding China gained 2% in Q4. Now on to margins. Gross profit margin came in at 75.7% of total net sales for the fourth quarter of 2025, versus 64.7% of total net sales in the comparable quarter a year ago. The year-over-year rise in gross profit resulted mainly from the timing of recognizing the cost of sales tied to the December 2024 China shipment, lower period costs stemming from cost reductions put in place during the first quarter of 2025, and the scaling up of Swiss manufacturing, partly offset by larger inventory provisions. Total operating expenses reached $66.6 million in the fourth quarter of 2025, compared with $59.6 million a year earlier. Operating expenses for the quarter encompassed $11.2 million in costs tied to the company's terminated merger transaction with Alcon and $0.7 million in restructuring costs. When those merger and restructuring costs are excluded, operating expenses for Q4 2025 totaled $54.7 million, which is 8.2% lower than the comparable quarter last year. The cost actions we took in 2025 undid the expense growth seen in earlier years, and we delivered substantial cost savings during 2025. As revenue comes back, we plan to keep up this cost discipline, which should put the company in position to return to profitability. Since our proprietary products are capable of earning robust gross margins, our operating margin could be quite high provided we carry out our plans effectively. Adjusted EBITDA for the fourth quarter of 2025 was a loss of $200,000, versus a loss of $20.8 million in the same quarter last year. This year-over-year gain in adjusted EBITDA came mainly from higher gross profit and reduced operating expenses prior to merger and restructuring expenses, partly offset by merger and restructuring expenses. Moving to our balance sheet; we finished the quarter with roughly $187.5 million in cash, cash equivalents and investments available for sale, a cash level we have kept relatively stable since Q2 in spite of considerable restructuring and merger-related expenses. STAAR carries no debt. Looking toward 2026, we are not offering financial guidance. That said, we do want to give some color commentary on how we believe 2026 will stack up against 2025. To begin, since we anticipate significantly growing our sales in 2026 relative to 2025 and since we achieved significant cost reductions in 2025, we are aiming for profitability in FY '26. Next, even as we push on profitability, our expectation is that gross margin will come in a bit below '26 levels compared with '25, because during '26 we'll be selling inventory from our Swiss manufacturing facility that carries a higher cost, and reserves tied to product expiration will also grow, creating headwinds; through 2026 we'll aim to counter those added costs by way of higher ASPs, better yields, and greater efficiency in our manufacturing, which ought to produce tailwinds in 2027. Third, 2025 brought us substantial savings on operating expense. Looking at 2026, our plan is to hold the operating expense run rate at amounts broadly in line with the $225 million target we shared with investors during Q1 2025. Last, though cash will decline a little in the near term, we anticipate returning to cash generation during the back half of the year and finishing 2026 with a cash balance above that of 2025; with that, I'll hand the call back to Warren. Warren?

Warren Foust executive
#4

Appreciate that, Deborah. So, putting it all together: 2025 was a transitional year. When it comes to 2026, execution is the focus. China has been stabilized on our end. Costs have been brought to the right size. Swiss manufacturing is being scaled up. EVO+ acceleration is underway in China, and growth, profit and innovation are the things we're aligned around; differentiated Collamer material is something we hold, along with exceptional optical technology and a demonstrated capacity to take share in a myopia market that is very large and still expanding. We're acting fast so that each employee gets what our growth, profit and innovation priority means and holds measurable objectives linked straight to execution. The people on our team are talented and very capable. We understand change can be hard, yet it also brings excitement along with promise and opportunity; efforts are underway to reignite the organization around sustained long-term growth. Alignment exists between our Board and leadership team. The strategy we have is clear, and disciplined execution plus long-term shareholder value creation are what we're focused on; what's ahead energizes us and we're confident in the path we're on. Thanks for your continued support. Operator, questions are next.

Tom Stephan analyst
#5

Starting off, regarding what's sitting with distributors. Warren, did those cuts keep going through Q1, or have things leveled off since Alcon is now in the rearview? And thinking about that, could you offer any boundaries for how we should frame Q1 and sales versus the $77 million in 1Q '24? It's March now. Honestly, I believe Chinese New Year wrapped up today; so any thoughts on 1Q revenue would also be useful; then I have a follow-up.

Warren Foust executive
#6

Sure. Appreciate you asking. Honestly, we're quite happy with where we've gotten on managing inventory. I genuinely like both the improvement and the supervision. There's a fresh leader stationed in Asia Pacific and China. A very capable, highly seasoned senior VP has come aboard, and this person is assisting with that effort. We review inventory every week; so our grasp is far better than it once was. It'll never be flawless, but our understanding is far better than before. So we observed inventory at the close of 2025 being brought down entirely beneath or exactly at contractual thresholds when we finished 2025. And we keep seeing very steady inventory positions at our distributor; actually, we're slightly under the 6-month contractual level we mentioned earlier; so inventory is in a solid spot. We believe we're set now as the market begins to recover and we'd see what the market will deliver. So that covers inventory. And regarding just the Q1, you heard Deborah's remarks, clearly we won't be giving guidance. But what we'd say is we're happy with how '25 finished in China end market. 2024 proved a very tough year; that was, in our view, a double-digit drop in in-market demand, which during 2025 bounced back to a pleasant sort of mid-single-digit level, and we think we'll see that as we moved out of '25 into '26; so we stay optimistic.

Tom Stephan analyst
#7

Understood, that sounds excellent. As for my next question, it's a bit more big-picture, so let's pull back for a moment. Warren or Deborah, perhaps you could take some time to talk about the current state of the company's health and how it stacks up against where things stood before Alcon. I'm a bit curious whether this factors in at all, either positively or negatively, when we consider both the near term and the long term and think about where the company is headed?

Warren Foust executive
#8

Sure, that's a solid question. I'll kick things off, and perhaps Deborah can chime in, since I think she has accomplished a great deal during 2025 on the financial front to truly bring us to a sound position. You'll recall that we allowed costs to balloon ahead of the Alcon merger agreement. And we truly regained command of that beginning in the Q1 2025 period. So I think as we moved through the year, in spite of everything happening with the disruption—and there was plenty of disruption, especially during Q4, which we can get into—we brought our costs into alignment, and we've maintained that discipline through '25 and we expect to carry it into '26, and our intention is to ensure we hold onto that discipline. So from the perspective of managing costs, that's excellent. The focus now is on rebuilding revenue. You've heard us describe this 3-pronged approach. Let's increase our revenue, let's broaden our profit margin, and then we need to speed up our innovation; and we have the organization, as we see it, even at this early stage in our new positions, united around those 3 key areas. So I think what you'd observe is that following the Alcon transaction, we have a Board that is very much on the same page. The Board along with the management team, we're all after the same objective. We're after growth and profitability. The organization, I believe, is glad to have moved beyond the disruption. And so the question now becomes whether we can get out there and deliver; and I'm confident that we possess the skilled team to guide us in doing so.

Iseult McMahon analyst
#9

Ryan couldn't make it, so this is Izzy filling in. First off, I get that you're steering clear of giving guidance for 2026, and I did catch what you said there, Tom, but I wanted to ask — or maybe nudge you a bit further. So when we look at how China's end market demand came in up mid-single digits while everything else declined — I believe your figure was roughly 2% beyond China — I'm wondering whether low single-digits is a reasonable assumption for 2026 as a whole? Any growth — or really any qualitative color you could offer on growth — would help a lot as we begin building our models.

Warren Foust executive
#10

Appreciate that, Izzy. Let me make sure I've got it right. Are you asking about that 2% figure we posted this quarter outside China? Is your question focused on ex-China? Or are you getting at something different?

Iseult McMahon analyst
#11

When we consider the overall shape of the business, weighing China's performance against what you're achieving everywhere else combined, would you say low single-digit growth is a solid target, or is that something STAAR could realistically hit in 2026?

Warren Foust executive
#12

Understood. That's a fair question. To be honest, 2025 requires some framing, especially when it comes to Q4. We saw a great deal of upheaval. And we observed our distribution partners across the globe, not only in Asia. We saw them deciding what to do about their stock levels. Picture yourself as a distributor anticipating a deal you figure will probably cost you your position, so you'd trim your inventory down. You'd probably pull back on funding certain critical initiatives that could otherwise bring in revenue for your business, and so forth. So all of that unfolded, most notably in Europe, where the European figures came in quite weak for Q4. We believe those outcomes were mostly driven by that upheaval, and that upheaval has now passed. Therefore our optimism about the ex-China business sustaining growth remains as strong as it has ever been. Obviously, surgeons are stepping away from LASIK and gravitating toward lens-based refractive surgery, opting for Collamer, which has existed for 30 years; within the phakic IOL space, we're the sole player with that kind of history. They're selecting ICLs. So that momentum is carrying forward, in our view. Whether in China or outside it, we believe we can keep that momentum going. As you noted, we aren't providing guidance on what that figure will ultimately be, but we're happy with our current position.

Iseult McMahon analyst
#13

Understood. Turning to how distributors behave, could you go into more detail regarding the particular structural adjustments you've implemented in those contracts — especially in China — that are going to stop any kind of inventory accumulation like the sort we experienced in '24 and '25?

Warren Foust executive
#14

Absolutely. As I said earlier, it will never be flawless; so I don't want to act as though we have complete knowledge of China right down through each layer of subdistribution, first tier, second tier, holding companies for the hospitals, and then out to the enormous quantity of hospitals across China. What I'd put to you is that our process is now considerably better. Those figures come to us each week. We grasp what the number — the shipments moving from our distributors further down into the distribution network, plus the returns filed against those shipments. As a result, we possess a — it serves as a proxy for net sales. It isn't an actual net sales figure; yet given that inventory levels have now rightsized in China, we currently believe we hold a solid proxy for what in-market demand is like.

Brad Bowers analyst
#15

My first question is probably about China. The second quarter has traditionally been the busy season. Clearly, last year that picture got muddied by what happened with the distributors. Still, I'd like to hear how we ought to think about modeling 2Q. Do we still expect that seasonal pattern? And is there anything early you're seeing that suggests the momentum we normally get will show up again in China this year?

Deborah Andrews executive
#16

Deborah here. From a seasonality standpoint, we do anticipate that Q2 and Q3 will remain very strong for STAAR in 2026, just as they have been historically. So please don't look for any meaningful shifts there.

Brad Bowers analyst
#17

All right, that's useful. So perhaps a broad question as well — what should our framework be for weighing priorities, growth in the U.S. against growth in China? Clearly, China has traditionally served as a stabilizing force for the business. How ought we to approach returning to that, as opposed to speeding up certain U.S. businesses, and once more, how do we rank each?

Warren Foust executive
#18

Yeah. Well — that's a fair question. Look, the progress we're achieving in the U.S. makes us proud. We keep witnessing success there. You saw us adjust our cost structure to the right size during the prior year. A portion of that related to the U.S. business itself. A portion was simply global footprint, since a great deal of our headquarters — our headquarters certainly, though a great deal of our infrastructure too — sits in the U.S. So you saw us dial that back while still enjoying solid double-digit growth in the U.S. Thus it's merely a smaller business compared with the larger business beyond the U.S., especially China, of course, Japan our second, plus Korea and Southeast Asia, India standing for a major opportunity, not to mention our activities in Europe; and so we'll keep investing with — alongside our customers who invest in EVO ICL. We'll do so within the United States; we'll do so beyond the United States as customers want to partner with us. Once more, we're seeing surgeons and our customers; we're seeing patients request alternatives to laser vision correction that calls for corneal tissue removal. They're shifting toward the lens-based option that can be reversed. And so we're witnessing that; and when customers tell their potential patients about it, then we'll partner with them, and we'll direct our investments there. Yet China represents the largest opportunity for us. It stays that way; we'll keep doubling and tripling down there.

Gursimran Kaur analyst
#19

So, picking up where that last question left off, maybe Warren or Deborah, can you walk us through what the actual growth formula looks like going forward? What portion comes from China's ongoing rebound and expansion, and what portion comes from recovery, penetration, and mix outside China? Also, is it possible to return to those robust double-digit rates you had in China before last year, and roughly the mid-teens pace ex-China? Please just explain how we get back to where things stood before 2025, and how long that takes?

Deborah Andrews executive
#20

Yes. I appreciate the question. My view — I don't believe 2026 will bring the hyper growth we experienced in 2023 and earlier. Of course, that's what we're aiming for. At the moment, fortunately, our Board takes a very long-term perspective on the company. And although we do anticipate solid worldwide growth for the company in 2026, I'd add a note of caution: I don't anticipate 20%, 25% growth, even though that is absolutely what we're striving toward, and that is absolutely the potential, no doubt.

Gursimran Kaur analyst
#21

Got it, that's really useful. And perhaps staying with China for a moment — I appreciate the remarks about the EVO+ launch. How should we frame the competitive picture for 2026? And could you offer any color on the ASP gap in China between EVO+ and EVO? And within the 2026 China growth algorithm, how much comes from price rather than volume, underlying demand, and an improving macro backdrop?

Warren Foust executive
#22

Yeah, good question, Simran. What I'd say is — and this ties in with what Deborah said earlier, since I think the two are connected — we remain dramatically underpenetrated when you look at refractive surgery relative to the size of the myopia epidemic worldwide. China is no exception. In fact, they're out in front on that. India might be right alongside them. So as people who want to make a dent in that epidemic, we're all in it together. Lens-based refractive surgery keeps growing, though that's only one part of the picture. So I believe there will be ample opportunity for us, and ample opportunity for competitors too. On the competition, look, we treat it very seriously. It's slightly flattering, honestly, that phakic IOLs are beginning to grow; I think that simply reflects that LASIK is declining in most markets and people are seeking a different treatment route. And this reversible option, I'd say, is genuinely attractive to the patient, or to potential patients; so it's a strong validation and we're pleased with it. Lots of companies have shown up as competitors before, and none of them are Collamer lenses; they're acrylic lenses, of various kinds, but that usually produces a stiffer structure. History shows that of the many who've arrived, only a handful have actually remained in the market. So Collamer sets us apart, 30-plus years. We got a pretty substantial head start in the market. So we're capitalizing on that, but we can't simply depend on it. We also need to keep innovating. That's why it matters that we bring products such as EVO+ into the Chinese market, so we can expand. Which brings me to your ASP question. What we've observed so far is considerable enthusiasm for EVO+. So that pleases us. And we'll keep working to scale up our Swiss plant so we can meet the demand. We are seeing a premium. We aren't disclosing that premium. You can guess why — it's a competitive advantage for us. What I will say is that customers notice the difference and patients are paying for that difference. So we'll see how it develops. It's still very early. I wouldn't read too much into it at this point, but the early progress makes us happy.

John Young analyst
#23

I'd like to add a question about what was said regarding EVO+ and its China launch. If my memory of the plan serves, one piece involved protecting against value-based purchasing in China. At this moment, are you encountering any pressures — or any for the traditional EVO lens — stemming from VBP in China? Also, are any anticipated?

Warren Foust executive
#24

Yeah. Regarding VBP, nothing has reached us. So here's my take: for VBP to occur, it generally takes place within the public market. It's possible in the private market as well. Dental has instances of this; and I believe in certain provinces, they've even attempted to examine orthokeratology. Yet nothing regarding VBP has come to our attention. Keep in mind that our rival, the Loong Crystal you've been hearing about, doesn't yet offer a toric version. Typically, the government only becomes interested once several competitors exist in the market; predicting whether it will or won't happen is beyond us, and we wouldn't attempt it. Still, to address what you asked, not a single thing about VBP has reached us, and thus far, things look good.

John Young analyst
#25

Great. Then, in your prepared remarks, you also mentioned how important the people within the organization are. I'm just curious: outside of the restructuring, given all the changes that have been happening, has turnover been higher than usual anywhere in the organization?

Deborah Andrews executive
#26

No. On that front, things have remained fairly stable. Our team is wonderful. The employees across this organization are wonderful. To be very honest, all of them are quite happy that the Alcon transaction fell through, since they enjoy working here, and we enjoy having them; so yes, so far, so good on that front.

David Saxon analyst
#27

I'd like to hear your perspective on which year had no stocking dynamics in China, so we can better understand what constitutes a typical year for China sales. For instance, would you consider 2023, at 185, a clean year when you factor in channel inventory — not that we'd necessarily go back to that in '26, but looking at the near term?

Warren Foust executive
#28

It sounds like a simple question to respond to, but the truth is China was experiencing — had been experiencing such an extreme hypergrowth phase that the distributors — the one distributor at that point, and later the 2 distributors once HTDK came on board — were making every effort to secure inventory, get people trained, and push it out into — keep in mind, we're talking about thousands of hospitals across a very large and diverse nation. So I can't say when you'd determine that in-market demand stopped in a manner that caused backchanneling or backfilling of inventory at the distributor or at any other point within that distribution channel. So I'm not sure that question has an answer. What I can say is that going forward, we have a very solid understanding of our inventory position, and strong controls are in place so that we won't let that happen to us again; and so we feel good about the contractual inventory levels with our importers, we feel better about what appears to be stabilization of the China business in 2025, and we're excited for a clean start in '26.

David Saxon analyst
#29

All right, that sounds good. For my next question, I'd like to shift focus to the U.S. and hear how the strategy is coming along. What changes have taken place since the first half of last year? Where are things working well? Which parts could use some reworking?

Warren Foust executive
#30

Sure. The U.S. team we have is excellent. The individuals leading that group are outstanding. What I can share is that a few years back, you may recall the phrase Highway 93 — and at that point, there were indeed 93 customers, but the concept wasn't truly meant to stay at 93 customers. The idea behind it was a way of thinking: concentrate on those customers who are ready to work alongside us and who wish to promote EVO ICLs as a choice for their patients. That group has since grown that roster, and their real accomplishment has been digging into the financials of turning EVO ICL into a stronger business for these refractive surgeries — pardon me, these refractive surgeons who are looking to expand their practices. They'll paint a picture of a market — a refractive market that isn't contracting. Instead, it's changing, moving away from LASIK, which involves removing corneal tissue, and toward a reversible option that, when the price is set right, when the staff is trained right and thus the message to a prospective patient is delivered right, represents a genuinely lucrative opportunity for those practices. So that mission is what drives their focus. Their training is solid and their messaging is consistent, and they're carrying it out. You witnessed the 2025 results with growth in the double digits, and we're eager to see what they accomplish this year; plus they're achieving it on a tight budget compared to a few years back. We were throwing money away in the U.S. It was going to the wrong areas. I took away many lessons from that. I was here witnessing it firsthand. So I believe we're in a stronger position now.

Mason Carrico analyst
#31

I'll limit myself to just one. In that deck you released regarding the Alcon merger, there was wording about STAAR being unable to reach patients with lower diopters, who represent most refractive patients, and that contradicted what had been said earlier about progressing down the diopter curve. So could you address that messaging shift and explain how it actually shapes your strategic choices and approach going forward?

Warren Foust executive
#32

Yes, that's a reasonable question. Let me offer one small clarification, which is that this isn't a messaging change in the sense that we understand we must move down the diopter curve to be effective. We know that, even in the publication you mentioned, we achieved progress moving down the diopter curve, beginning at — I can't recall precisely, but minus 12 diopter down to roughly minus 9, minus 9.5. At this stage, we need to keep moving down the diopter curve, and that's difficult. It's difficult because in markets globally where customers have put money into infrastructure for treating patients using laser technology, they expect those technologies they've funded to deliver returns. So the truth is we will continue fighting that battle. We will continue advocating appropriately for our customers to think about EVO for lower diopters. We understand that the greater the patient's higher diopter refractive error correction, the more tissue must be removed, which causes dry eye, which leads to other consequences. Therefore, we will keep pushing. Our progress hasn't matched what we'd hope for. We always aim for more. Certain markets will perform better. Certain markets will still have enormous numbers of high myopia cases. Consider Asian markets such as China, such as India, such as Korea and Japan — there are abundant high myopia patients to treat. Still, we will sustain the fight, and I'll interpret your question as encouragement that we must do so.

Adam Maeder analyst
#33

I've got two things. First, regarding China — plenty of questions have come up already, though I'm not certain we've covered what's expected for ICL in-market growth in FY '26. It seems like conditions began settling somewhat during 2025. Should we anticipate additional recovery in the coming year? Any extra detail you could offer would be welcome. Then I have a follow-up.

Warren Foust executive
#34

Many of the identical difficulties we've been battling — the ones we battled throughout 2025 — remain present. Macro headwinds persist in China. They're simply improving. You can see Chinese stock markets performing much better, yet the housing market still appears somewhat weak. They're exiting Chinese New Year. I'm not sure solid data exists on that yet. My sense is the sentiment coming out of Chinese New Year seemed favorable. We'll find out. The government stimulus introduced across 2024 and afterward 2025, in our view, is beginning to deliver results. Perhaps it's partly what's fueling even that stock market jump. So we're cautiously optimistic regarding their economy. How much that will affect in-market sales is too difficult to determine. What we can share is that Q4 of 2025 represented a pleasant acceleration compared with earlier quarters for in-market sales. That positioned us, for the entirety of '25, at roughly what we think was single-digit in-market demand growth against the year before; so ideally we capture some of that momentum as we exit Q4. Ideally, the economy remains as it's been or improves, but it's still too soon to know, which explains the hesitancy to provide guidance.

Adam Maeder analyst
#35

All right. That's really useful, Warren. Thanks for the detail. For my second question, I'd like to ask about innovation and how we're prioritizing it. I believe that came up a few times on this call and in the shareholder letter. So what can you share with us right now regarding the innovation pipeline, and in particular, how should we be thinking about the possibility that some of these new products receive regulatory clearance and what that means for models?

Warren Foust executive
#36

Yes. Excellent question, since this is the third pillar of our strategy, and honestly, it's an area where we have not performed the way we'd like to. EVO is fantastic. The Collamer material stands apart. And at this point, the responsibility falls on us to launch new products. I'm proud of V5, and proud that we're bringing EVO+ to China; we believe that will set us apart. We'll also launch the Lioli injector, which represents incremental innovation. The lens remains the star of the show, but this will give our customers a great way to inject EVO into their patients. Beyond that, we have a number of projects underway behind the scenes. Hopefully we can provide updates, perhaps on future calls, about time lines. Consider milestones such as when we begin first-in-man treatments and when we pass through other stage gates in the design control process, which matters a great deal in R&D. We'd like to offer that visibility, we're just not ready to do so at this point.

Connie Johnson executive
#37

That's all the phone questions we have so far.

Warren Foust executive
#38

Okay. Operator, it sounds like there's no more questions?

Operator operator
#39

That wraps up the Q&A portion as well as this conference call. We appreciate your participation in today's presentation. You are free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete STAAR Surgical Company transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to STAAR Surgical Company earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.